Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GenomIdea
Ibaraki-city, Osaka-fu, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
GenomIdea developed the GEN0101 platform—an HVJ-E-based immunotherapeutic agent—tested in early-phase trials for advanced melanoma and malignant pleural mesothelioma. The tuberculosis vaccine program targeting IL‑12 was discontinued. GEN0101 showed immune activation properties but did not advance to late-stage development as an independent company.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineBiologicGene therapy
- Industry
- Biotech
02
Partnerships
TSD JapanAnGes MG/AnGes Inc.
Beyond the preview
Go deeper on GenomIdea.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenomIdea.